Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Rhea-AI Summary

Kyverna Therapeutics (Nasdaq: KYTX) announced that CEO Warner Biddle will present at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 1:00 p.m. GMT.

A live webcast will be available via the Investors section of Kyverna's website at ir.kyvernatx.com, and a replay will be posted for approximately 90 days after the conference.

EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Monday, November 17, 2025 at 1:00 p.m. GMT.

A live webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for approximately 90 days following the conference.

About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through late-stage clinical development with registrational trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis and rheumatoid arthritis, to inform the next priority indications for the Company to advance into late-stage development. Additionally, its pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats, including efficiently expanding into broader autoimmune indications and the potential to increase patient reach with KYV-102 using its proprietary whole blood rapid manufacturing process. For more information, please visit https://kyvernatx.com.

Contacts: 
Investors: InvestorRelations@kyvernatx.com 
Media: media@kyvernatx.com 

FAQ

When will Kyverna (KYTX) present at the Jefferies London Healthcare Conference?

Kyverna will present on Monday, November 17, 2025 at 1:00 p.m. GMT.

Who from Kyverna (KYTX) will present at the Jefferies conference?

Kyverna's Chief Executive Officer, Warner Biddle, will deliver the presentation.

How can investors watch Kyverna (KYTX) present at the Jefferies London conference?

A live webcast will be available via the Investors section at ir.kyvernatx.com.

Will there be a replay of Kyverna's (KYTX) Jefferies presentation and for how long?

Yes. A replay will be available on the company website for approximately 90 days after the conference.

What topics will Kyverna (KYTX) likely cover at the Jefferies Global Healthcare Conference?

The presentation will focus on Kyverna's clinical-stage cell therapy programs for autoimmune diseases.

Where is the Jefferies Global Healthcare Conference taking place for Kyverna's (KYTX) presentation?

The conference presentation will be held in London, United Kingdom with a simultaneous webcast.